Astellas Pharma Inc

This study tested the safety and effectiveness of enzalutamide (Xtandi) in 52 Indian men with metastatic castration-resistant prostate cancer that had worsened after chemotherapy. Participants took enzalutamide daily while continuing hormone therapy. The main goal was to see how …

This study looked at how safe and effective peficitinib is for people with rheumatoid arthritis (RA) in everyday medical practice. About 3,000 patients who were starting peficitinib for the first time took part. Researchers tracked side effects and measured disease activity using…

This Phase 2 trial tested whether adding OSI-906 to erlotinib (Tarceva) as maintenance therapy could help people with advanced non-small cell lung cancer (NSCLC) who had not progressed after initial chemotherapy. The study enrolled 205 participants and compared the combination ag…

This study tested a single dose of a new drug called ASKP1240 in 50 people who just received a kidney transplant. The goal was to see how the drug moves through the body, how safe it is, and how well it works. Participants were randomly assigned to get the drug or a placebo, and …

This Phase 2 trial tested whether adding the experimental drug OSI-906 to the standard targeted therapy erlotinib (Tarceva) could help people with advanced non-small cell lung cancer that has a specific EGFR gene mutation. The study enrolled 88 people who had not received prior c…

This phase 3 study tested the drug enzalutamide in 395 Asian men with metastatic prostate cancer that had stopped responding to standard hormone therapy. Participants had not yet received chemotherapy. The study compared enzalutamide to a placebo to see if it could delay rises in…

This study tested a drug called gilteritinib (Xospata) alongside standard chemotherapy in 97 people newly diagnosed with acute myeloid leukemia (AML), especially those with a FLT3 gene mutation. The first part aimed to find the safest dose, and the second part measured how many p…

This study tested a medicine called fezolinetant to see if it is safe for Japanese women with hot flashes from menopause. About 277 women took either the medicine or a placebo (a dummy pill) once a day for up to a year. The main goal was to check for side effects and how well the…

This study tested fezolinetant, a non-hormonal medicine, in 410 Japanese women with menopause-related hot flashes. Participants took either a low or high dose of fezolinetant or a placebo daily for 12 weeks. The goal was to see if the drug reduces the number and severity of hot f…